Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial
Jean‐Marc Chavatte, Pei Xiang Hor, Suma Rao, Isaac Kai Jie Kam et al.
Citations
1 citations
Journal
Vaccine
Topics
SARS-CoV-2 and COVID-19 Research
Field-Weighted Citation Impact (FWCI)
0.39
article
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial
Jean‐Marc Chavatte, Pei Xiang Hor, Suma Rao, Isaac Kai Jie Kam, Lisa F. P. Ng, Chee Wah Tan, Sean Wei Xiang Ong, Barnaby Edward Young, Tau Hong Lee, Chiew Yee Loh, Yun Shan Goh, Vanessa Kexin Neo, Aileen Ying-Yan Yeoh, David Chien Lye, Nathan Wong, Lin‐Fa Wang, Daniel R X Lim, Siew‐Wai Fong, Ee Chee Ren, Laurent Rénia, Sapna P. Sadarangani, Po Ying Chia, Angéline Rouers, Anthony Torres‐Ruesta, Xuan Ying Poh, Yu‐Ling Huang, Terence J K Yoong, Raymond T. P. Lin, Wanni Chia
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
VaccineVol. 42(25)
Institutions
Agency for Science, Technology and Research (SG), University of Liverpool (GB), Nanyang Technological University (SG), Singapore Immunology Network (SG), Tan Tock Seng Hospital (SG), Duke-NUS Medical School (SG), National University Hospital (SG), National Centre for Infectious Diseases (SG), Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool (GB)